Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | ACLY | P53396 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3813522 | 1.00 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1TSHRTHRBTP53 | |
| Trifluoroacetic Acid SCHEMBL30705423 | 1.00 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1TSHRTHRBTP53 | |
| Trifluoroacetic Acid SCHEMBL27922651 | 1.00 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1TSHRTHRBTP53 | |
| Trifluoroacetic Acid SCHEMBL4531143 | 1.00 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1TSHRTHRBTP53 | |
| Trifluoroacetic Acid SCHEMBL2015479 | 1.00 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1TSHRTHRBTP53 | |
| Trifluoroacetic Acid SCHEMBL4772775 | 1.00 | — | — | |
| Trifluoroacetic Acid SCHEMBL375389 | 1.00 | — | — | |
| Trifluoroacetic Acid SCHEMBL1362836 | 1.00 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1TSHRTHRBTP53 | |
| Trifluoroacetic Acid SCHEMBL2484766 | 0.95 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1TSHRTHRBTP53 | |
| Trifluoroacetic Acid SCHEMBL4598430 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558971-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018119208-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| CN-101376659-B | Method for purifying camptothecine and derivative thereof | SHANGHAI BIOCOMPOUNDS CHEMLAB CO., LTD. (CN) | 2011-11-30 | — | — | CN | disclosed |
| US-7977334-B2 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity modulator, insulin resistance | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-12 | — | — | US | disclosed |
| WO-2011075630-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
| CN-101376659-A | Method for purifying camptothecine and derivative thereof | SHANGHAI NORTHCAROLINA CHEMLAB (CN) | 2009-03-04 | — | — | CN | disclosed |
| US-20080234278-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | TRIESELMANN THOMAS | 2008-09-25 | — | — | US | disclosed |
| EP-1781620-A1 | NOVEL BETA AGONISTS, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-09 | — | — | EP | disclosed |
| WO-2005108373-A1 | NOVEL BETA AGONISTS, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | WO | disclosed |
| US-20050245526-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234278-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | ALDH1A1 674/4885L3MBTL1 4117/4885TSHR 527/4885 |
| US-20050245526-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | ALDH1A1 674/4885L3MBTL1 4117/4885TSHR 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.